This poster, developed in collaboration with noted experts in breast cancer, was presented in December 2017 at the San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster highlights differences in expert and community practitioner treatment trends identified from an innovative online tool developed to help facilitate therapeutic decision making in metastatic breast cancer (MBC). In the first-line setting for patients with de novo HR+/HER2- MBC or with progression to MBC after (neo)adjuvant aromatase inhibitor therapy, experts were more likely to recommend a CDK4/6 inhibitor than community practitioners. In patients with triple negative MBC who were in visceral crisis, experts recommended combination chemotherapy more frequently than community practitioners who most often recommended single agent chemotherapy. Clinicians who initially chose a treatment option other than those recommended by the experts indicated that their use of the tool would change their choice of treatment in 62% of cases, showing that online tools can make a substantial impact in clinical decision making.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.